AI in private equity: 2026 statistics & benchmarks.
The numbers, each independently citable.
One fact per card: the figure, the named source, the date, and a verifiability grade. A = peer-reviewed/regulatory/audited; B = named top-tier press or primary company/analyst report; C = vendor/self-reported. Every figure below is Grade B — named primary research, self-reported survey data.
What these numbers mean for GPs and boards.
The lesson is not that AI in private equity is overhyped — it is that the 64-point gap between expectation (70% of GPs) and delivery (6%) is exactly where limited-partner diligence now concentrates. The 53% of LPs who screen a manager’s AI value-creation strategy are not asking whether portfolio companies use AI; they are asking whether anyone can prove it moved EBITDA.
For a board, the discipline that closes that gap is the same one that protects a deal: a named owner for each AI initiative, a pre-deployment baseline, and an audited delta — the structure behind The Proof Standard™. The same rigour applies before you buy: AI due diligence on a target’s AI claims is a downside-protection tool, not a box-tick.
Where AI shows up across the private-equity deal lifecycle.
Generative-AI use in private equity is still concentrated at the front of the funnel, not in execution. Per Deloitte’s 2025 GenAI in M&A Survey, current use splits 40% deal strategy, 35% target identification, 35% due diligence — with value creation and exit still largely manual.
- Sourcing & screening. AI ranks and de-duplicates targets across thousands of companies — the most mature use, but the one where a “proprietary AI sourcing edge” most needs LP-grade diligence, not a demo.
- Due diligence. 35% of GenAI M&A use sits here (Deloitte 2025). The board question is the inverse: is the target’s own AI a real moat or a slide? That is its own discipline — see AI due diligence.
- Value creation. Where the 70%-vs-6% gap (McKinsey 2026) actually lives: GPs expect portfolio EBITDA impact, few can yet prove it. This is the stage LPs now screen for.
- Exit. The least AI-penetrated stage today — and the one where a documented, audited AI value-creation story becomes a multiple argument at sale.
What these numbers do not mean.
All eight figures are Grade B — named primary reports, but self-reported survey data, not audited outcomes. “Use of generative AI in M&A” (86%) measures adoption in workflows, not proven ROI. “$1M+ invested” (88%) measures spend, not return. The “20% operationalised with results” figure is the portfolio firms’ own characterisation. Read these as adoption signals and an LP-pressure indicator — not as evidence that AI has yet moved returns at scale.
Private-equity AI questions, answered.
What share of private-equity portfolio companies use AI in production?
As of 2026, about 20% of PE portfolio companies have operationalised generative AI with concrete, measurable results, per Bain’s Global Private Equity Report 2025 (investors representing $3.2T AUM). The majority remain in testing and development, not production.
How are limited partners evaluating a GP’s AI strategy?
53% of limited partners rank a GP’s AI value-creation strategy among their top five manager-selection criteria, per McKinsey’s Global Private Markets Report 2026. LPs increasingly probe whether AI moved portfolio EBITDA — not whether portfolio companies merely adopted AI tools.
Where are PE firms using generative AI in deals?
Generative-AI use in M&A concentrates early in the funnel: 40% in deal strategy, 35% in target identification and 35% in due diligence, per Deloitte’s 2025 GenAI in M&A Survey. Execution-stage and post-close use remain comparatively rare.
Is AI in private equity delivering measurable returns yet?
Mostly not yet, on the firms’ own evidence: 70% of GPs expect high AI impact within three to five years but only 6% see it today (McKinsey 2026). Adoption figures — 86% use GenAI in dealmaking — measure activity, not audited return.
Will AI replace private equity?
No. AI is reshaping how private-equity work gets done — sourcing, diligence, portfolio operations — but the judgment that defines the asset class (which businesses to back, at what price, with what thesis) remains human. The firms that win treat AI as a value-creation lever and an LP-diligence requirement, not a replacement for investment judgment.
How are private-equity firms creating value with AI?
Across the deal lifecycle: AI-assisted sourcing, faster due diligence (35% of GenAI M&A use, Deloitte 2025), and portfolio-company operational gains. But only ~20% of portfolio companies have operationalised GenAI with measurable results (Bain 2025) — value creation, not adoption, is the bar that LPs and exits now reward.
What do private-equity firms look for in an AI advisor?
Operator credibility over slideware: someone who has shipped AI in production, can run LP-grade diligence on a target’s AI claims, and can prove portfolio impact with a baseline and an audited delta — the structure behind The Proof Standard™ — rather than a maturity-model deck.
How these figures were selected.
Each statistic was re-verified against its named primary source and corroborated across at least two independent reports before inclusion; figures traceable only to vendor PR or single aggregators were dropped. All figures here are third-party (Grade B). Primary sources: Bain & Company, Global Private Equity Report 2025 (survey of investors representing $3.2T AUM, Sept 2024); McKinsey & Company, Global Private Markets Report 2026 — Private Equity; Deloitte, 2025 GenAI in M&A Survey (1,000 senior investors). First-party vs third-party: 100% third-party today. Update cadence: quarterly.